Costs Gates Secured Hundreds Of Millions Within Profits From mRNA Stock Sales Before Suddenly Modifying Tune On Vaccine Technologies
Once an mRNA evangelist, Gates now dismisses the technology as low quality, after banking a 15x return on investment.
Bill Gates guaranteed hundreds of millions of dollars in profits from his foundation’s impeccably timed investment in BioNTech — the Pfizer partner for its mRNA Covid shots — before significantly reversing course and continuing to openly cast question on the whole of mRNA technology.
In reviewing SEC filings, The Dossier has found how the Gates Foundation’s holdings within BioNTech went from 1, 038, 674 shares in order to 148, 674 shares throughout the third quarter of 2021, downsizing the Gates position in the mRNA vaccine producer by 86 percent of shares held.
As you can see below, Gates just so happened to period the market perfectly, selling the particular shares during BioNtech’s best performing quarter.
In September of 2019, just months before Covid hysteria made its way with the world, The Gates Basis secured its shares in the Pfizer vaccine partner through a pre-IPO equity deal with a good agreed upon purchase price of $18. 10 per share. By having an average sale price of around $300 per share within Q3 of 2021, this means that the Gates Foundation banked roughly $260 million within cash from the sale, with $242 million being untaxed profit, given that the money had been invested through the foundation.